Omnitrope Gains Final EU Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz will launch the Genotropin follow-on in Germany and Austria in the coming days.
You may also be interested in...
Sandoz Will Launch Biosimilar Epoetin Alfa In Europe At Up To 30 Percent Discount To Branded Products
EU approval further demonstrates need for U.S. follow-on pathway, Sandoz VP-Global Head of Biopharma Development Ajaz Hussain tells “The Pink Sheet” DAILY.
Sandoz Will Launch Biosimilar Epoetin Alfa In Europe At Up To 30 Percent Discount To Branded Products
EU approval further demonstrates need for U.S. follow-on pathway, Sandoz VP-Global Head of Biopharma Development Ajaz Hussain tells “The Pink Sheet” DAILY.
EU’s CHMP Gives Nod To First Biosimilar Epoetin Alfa Formulations
Sandoz is set to launch its biosimilar, Binocrit, in 2007 following commission approval, the firm tells “The Pink Sheet” DAILY.